Drug Delivery Technologies: Commercial Prospects 2012-2022


January 31, 2012
167 Pages - SKU: VSG3804026
License type:
Table of Contents Related Reports
Drug Delivery Technologies: Commercial Prospects 2012-2022

  enlarge


How to find industry trends and revenue prospects there

What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions.

This decade, many commercial opportunities for improved drug delivery exist. You discover sales predictions to 2022 at world market, submarket, application and national level.

In particular, our report forecasts six submarkets to 2022, showing you potential revenues:
  • Oral delivery
  • Inhaled delivery
  • Transdermal delivery
  • Ocular delivery
  • Nasal delivery
  • Implants for drug delivery.
The study discusses 3M, Catalent, Alkermes, Generex Biotechnology, pSivida and many other technology providers, letting you assess outlooks for the industry and market.

How will biological drugs using the technologies perform from 2012? You find overall revenues from nine pharmaceutical areas predicted to 2022:
  • Monoclonal antibodies
  • Insulins
  • Erythropoietins
  • Interferons
  • G-CSF agents
  • Recombinant coagulation factors
  • Other therapeutic proteins
  • Biosimilars and related agents
  • Vaccines.
Our investigation gives you business research and analysis with many forecasts.

Where is drug delivery heading? Technologies and applications giving improved clinical efficacy, patient convenience and treatment compliance will achieve success.

Drug delivery R&D is promising. Suppliers and users of the technology will benefit. Our calculations show you the potential for expanded revenues to 2022.

Which areas of pharma will benefit most? Drug delivery technologies offer many opportunities for pharma line extensions and product lifecycle management, benefiting a wide range of drugs. Biologicals and vaccines will profit especially. You see how.

In our analysis, the drug delivery technology industry will achieve high revenue growth from 2012 to 2022. In particular, greater use of injectable drugs and vaccines worldwide will stimulate demand for innovative delivery systems.

We find wide scope for novel and improved drug delivery from 2012 onwards, seeing many sales opportunities for products and services there. Our report explains.

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers in our work.

Revenue forecasts, market shares, developmental trends and discussions

In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (SWOT and STEP) and discussion of technologies, existing and in development. You receive 90 tables and charts and four research interviews.

Advantages of Drug Delivery Technologies: Commercial Prospects 2012-2022 for your work

In particular, this study gives you the following knowledge:
  • Find potential revenues to 2022 for the world market and submarkets
  • See market forecasting to 2022 for US, Japan, EU5, China and India
  • Receive forecasts to 2022 for drug classes using the systems
  • Assess leading companies, discovering activities and outlooks
  • Review technological developments, assessing trends and prospects
  • Investigate competition and opportunities influencing revenues
  • Find out what will stimulate and restrain the industry and market
  • View opinions from our survey, receiving four interviews.
There, you find an original mix of quantitative and qualitative analyses with independent predictions. Receive data that only our report contains, harnessing our pharma knowledge.

Through our analytical methods we keep you informed about commercial trends and prospects. By getting our report now, you could find that information before your competitors.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


Additional Information


Report Excerpt

Visiongain believes that this class will show steady, low single-digit growth throughout the forecast period, 2012 to 2022. Revenues will increase to $5.43bn in 2016 and $5.78bn in 2022 (Table 4.15-4.16 and Figure 4.6). The initial growth of sales in this class will be due to steady increases in sales of the current leading drugs. The introduction of new drugs will also contribute to growth of this class, our analyses reveal. That product category will be a main revenue growth driver for drug delivery technologies – products and services.

Companies Listed

3M Drug Delivery Systems
Abbott Laboratories
Actelion Pharmaceuticals
AERAS
Aerogen
Alexion Pharmaceuticals
Alimera Sciences
Alkermes
Alpha M.O.S.
Altea Therapeutics
Alvogen
Amgen
Amylin Pharmaceuticals
Antigen Express
Apotex Corp
Applied Pharma Research (APR)
Aptalis
Aptuit
Aradigm Corp
Arakis
Ascend Therapeutics
Astellas Pharma
AstraZeneca
Axcan Intermediate Holdings
Axcan Pharma
Bausch & Lomb
Baxter International
Bayer
Behring
Berna Biotech
Biocon
Biogen Idec
Biological E. Limited
Biopartners
Biotech Pharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Cardinal Health
Catalent Pharma Solutions
Celgene Corporation
Cell Therapeutics
Centocor Ortho Biotech
Cephalon
Chiron Corporation
Cima Labs (Cephalon)
Circassia
Columbia Laboratories
Conba Pharmaceutical
CSL Biotherapies
CT Arzneimittel
Department of Health and Human Services (US)
Dong-A
Dr. Reddy's Laboratories
E. Merck KG
E. R. Squibb & Sons
EKR Therapeutics
Elan Pharmaceuticals
Eli Lilly
Elite Pharmaceuticals
Emisphere Technologies
Endo Pharmaceuticals
Ethypharm
Eurand Pharmaceuticals
Eurofarma
European Medicines Agency (EMA)
Flynn Pharma
Food and Drug Administration (US FDA)
Fresenius Group
Gate Pharmaceuticals
Genentech (now part of Roche)
Generex Biotechnology Corporation
geneRx+
GeneScience
Genmab
Genta
Genzyme Corporation
Gilead Sciences
GlaxoSmithKline (GSK)
Glycologic
Hisamitsu Pharmaceutical Co.
Hospira
Human Genome Sciences
Immunex Corporation
Intercell
Johnson & Johnson (J&J)
Labtec
Leiras OY (Nycomed)
LG Life Sciences
MannKind Corporation
Merck & Co.
Merck Serono
Mipharm
MonoSol Rx
MundiPharma
Mylan
NanoPass Technologies
National Institute for Health and Clinical Excellence (NICE, UK)
Nektar Therapeutics
Novartis
Noven Pharmaceuticals
Novo Nordisk
Novogyne Pharmaceuticals
Organon Teknika
Otsuka Pharmaceuticals Co
Pacira Pharmaceuticals
Par Pharmaceutical
Pfizer
Pre-clinical Partnerships
ProFibrix
pSivida
Ranbaxy Laboratories
Recipharm
Research Foundation for Microbial Diseases of Osaka University (BIKEN)
Roche
Romark
Sandoz (part of Novartis)
Sanofi (formerly sanofi-aventis)
Sanofi Pasteur MSD
Schering-Plough Corporation (now part of Merck & Co.)
Shire
Sigma-Tau Pharmaceuticals
SkyePharma
Sosei Group Corp.
Spectrum Pharmaceuticals
Statens Serum Institut
Strativa Pharmaceuticals
Talecris Biotherapeutics
Team Consulting Limited
Teva Pharmaceutical Industries
The Blackstone Group
TRION Pharma
UCB
University of Copenhagen, Denmark
Vectura Group
Watson Pharmaceuticals
Whitehall Laboratories
Wyeth (now a part of Pfizer Inc.)
Zhejiang CONBA Pharmaceutical Co.

More Drug Delivery reports by Visiongain

Pre-Filled Syringes: World Market Outlook 2011-2021 by Visiongain
How will the pre-filled syringes market develop this decade? Our new report shows you potential revenues to 2021 for that technology and its applications, discussing ...
World Diabetes Drug Market 2011-2021 by Visiongain
Where will revenue growth occur in the diabetes treatment market? Our new report shows you the potential that drug market offers from 2011 to 2021, ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Drug Delivery Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!